AU2022323513A1 - Method of treating posttraumatic stress disorder - Google Patents
Method of treating posttraumatic stress disorder Download PDFInfo
- Publication number
- AU2022323513A1 AU2022323513A1 AU2022323513A AU2022323513A AU2022323513A1 AU 2022323513 A1 AU2022323513 A1 AU 2022323513A1 AU 2022323513 A AU2022323513 A AU 2022323513A AU 2022323513 A AU2022323513 A AU 2022323513A AU 2022323513 A1 AU2022323513 A1 AU 2022323513A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- individual
- treatment
- ptsd
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000028173 post-traumatic stress disease Diseases 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 238000011282 treatment Methods 0.000 claims description 63
- 239000006186 oral dosage form Substances 0.000 claims description 38
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 claims description 18
- 230000036470 plasma concentration Effects 0.000 claims description 10
- 150000001200 N-acyl ethanolamides Chemical class 0.000 claims description 5
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 claims description 5
- 239000002621 endocannabinoid Substances 0.000 claims description 5
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 3
- 229940124036 Hydrolase inhibitor Drugs 0.000 abstract 1
- 101100013496 Mus musculus Aifm2 gene Proteins 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000004093 hydrolase inhibitor Substances 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 description 60
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 60
- 208000024891 symptom Diseases 0.000 description 23
- 230000008859 change Effects 0.000 description 18
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 11
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 11
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 8
- 230000007958 sleep Effects 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000000472 traumatic effect Effects 0.000 description 5
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 description 4
- 230000037007 arousal Effects 0.000 description 4
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 4
- 230000009760 functional impairment Effects 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 240000004308 marijuana Species 0.000 description 3
- 230000004630 mental health Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010034912 Phobia Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 201000001716 specific phobia Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- -1 Biaryl Ether Urea Compounds Chemical class 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 1
- 101001116937 Homo sapiens Protocadherin alpha-4 Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 102100024261 Protocadherin alpha-4 Human genes 0.000 description 1
- 206010068932 Terminal insomnia Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000008434 fear extinction Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163229387P | 2021-08-04 | 2021-08-04 | |
| US63/229,387 | 2021-08-04 | ||
| PCT/US2022/074469 WO2023015206A1 (en) | 2021-08-04 | 2022-08-03 | Method of treating posttraumatic stress disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022323513A1 true AU2022323513A1 (en) | 2024-02-22 |
Family
ID=83149040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022323513A Pending AU2022323513A1 (en) | 2021-08-04 | 2022-08-03 | Method of treating posttraumatic stress disorder |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240335441A1 (https=) |
| EP (1) | EP4380571A1 (https=) |
| JP (1) | JP2024529022A (https=) |
| KR (1) | KR20240046737A (https=) |
| CN (1) | CN118284419A (https=) |
| AU (1) | AU2022323513A1 (https=) |
| CA (1) | CA3227681A1 (https=) |
| MX (1) | MX2024001673A (https=) |
| TW (1) | TW202320779A (https=) |
| WO (1) | WO2023015206A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007011793D1 (de) * | 2006-10-18 | 2011-02-17 | Pfizer Prod Inc | Biaryl-ether-harnstoffverbindungen |
-
2022
- 2022-08-03 CA CA3227681A patent/CA3227681A1/en active Pending
- 2022-08-03 JP JP2024506897A patent/JP2024529022A/ja active Pending
- 2022-08-03 AU AU2022323513A patent/AU2022323513A1/en active Pending
- 2022-08-03 EP EP22761888.1A patent/EP4380571A1/en active Pending
- 2022-08-03 CN CN202280058527.2A patent/CN118284419A/zh active Pending
- 2022-08-03 US US18/294,129 patent/US20240335441A1/en active Pending
- 2022-08-03 KR KR1020247007299A patent/KR20240046737A/ko active Pending
- 2022-08-03 WO PCT/US2022/074469 patent/WO2023015206A1/en not_active Ceased
- 2022-08-03 MX MX2024001673A patent/MX2024001673A/es unknown
- 2022-08-03 TW TW111129103A patent/TW202320779A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023015206A1 (en) | 2023-02-09 |
| JP2024529022A (ja) | 2024-08-01 |
| MX2024001673A (es) | 2024-04-30 |
| CA3227681A1 (en) | 2023-02-09 |
| TW202320779A (zh) | 2023-06-01 |
| CN118284419A (zh) | 2024-07-02 |
| KR20240046737A (ko) | 2024-04-09 |
| US20240335441A1 (en) | 2024-10-10 |
| EP4380571A1 (en) | 2024-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220226262A1 (en) | Methods of treating doose syndrome using fenfluramine | |
| Sperling | The consequences of uncontrolled epilepsy | |
| US20230093150A1 (en) | Changing cognitive function with fenfluramine | |
| AU2016312526B2 (en) | Methods of treating lennox-gastaut syndrome using fenfluramine | |
| US20210299064A1 (en) | Method of treating patients with lennox-gastaut syndrome | |
| Hendershot et al. | Application of an alcohol clamp paradigm to examine inhibitory control, subjective responses, and acute tolerance in late adolescence. | |
| US20090054414A1 (en) | Rufinamide for the Treatment of Post-Traumatic Stress Disorder | |
| US20100069402A1 (en) | Treatment of Behavioral Disorders | |
| JP2023509720A (ja) | 認知障害の予防及び療法 | |
| JP2010534674A (ja) | 心的外傷後ストレス障害の治療用４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド | |
| DeVito et al. | Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects | |
| US20240335441A1 (en) | Method of treating posttraumatic stress disorder | |
| Middelboe et al. | Psychiatric sequelae of minor head injury. A prospective follow-up study | |
| Grasing et al. | Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals | |
| Baggott et al. | 3, 4-Methylenedioxymethamphetamine (MDMA): A review of the English-language scientific and medical literature | |
| Ozyurt et al. | Investigating the potential link between bruxism and obsessive-compulsive symptomatology: An exploratory study | |
| Rintakoski | Sleep bruxism–genetic factors and psychoactive substances | |
| Truong | SUBSTANCE USE AND HIV | |
| Conley et al. | Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M | |
| Dousset et al. | The impact of anti-craving medication on cue reactivity and abstinence in patients undergoing alcohol detoxification: some preliminary evidence from a retrospective event-related potentials study | |
| Demetriou et al. | Outpatient Intravenous Ketamine Protocol for Psychiatric Care at the General Hospital of Corfu | |
| Truong et al. | SUBSTANCE USE IN HIV POPULATIONS | |
| WO2026022492A1 (en) | Nitroxoline for use in the treatment and/or prevention of pain | |
| WO2025255215A1 (en) | Methods and compositions for treating sleep apnea | |
| Broadstock et al. | The effectiveness of pharmacological therapies for young people and adults with Autism Spectrum Disorder (ASD) |